Bullish Beta Stocks With Huge Potentials Returns: $MTDR $AROC $ZIOP

The Market Signal was created as a platform to help investors, if you own (NYSE:MTDR), (NASDAQ:AROC) or (NASDAQ:ZIOP), and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.


(Click link above or copy, paste and hit enter in your browser for your report)

Matador Resources Completes Expansion Of San Mateo Black River Plant


(Click link above or copy, paste and hit enter in your browser for your report)

Matador Resources Co. (NYSE:MTDR) has a beta of 4.83 which means though the stock is risky yet offers huge potential returns. The company has successfully completed the expansion and startup of the San Mateo's Black River natural processing facility in Eddy County in New Mexico. The expansion will add a designed inlet capacity of 200 million cubic feet per day of natural gas to the current inlet of 260 million cubic feet bringing total inlet capacity to around 460 million cubic feet per day.

The expansion processes natural gas from the company's Stebbins and Stateline areas. Also, the Black River plant is processing gas from the Rustler Breaks leasehold.

Archrock Services' Real Estate Assets To Be Auctioned


(Click link above or copy, paste and hit enter in your browser for your report)

Archrock Inc. (NYSE:AROC) is also another risky looking stock with the potential of huge returns and has a beta of 2.84. Some surplus Archrock Services' real estate assets are expected to be auctioned by William & Williams. The assets include office spaces, warehouses, and land parcels that will be auctioned on September 29. Also, the vacant residence in New Castle has been put on sale on an only auction at AuctionNetwork.com on September 28-30.

B Riley FBR's Tom Curran has maintained a buy rating on Archrock stock with a target price of $8.5. Currently, the consensus rating on the strong is a Strong Buy with an average target price of $9.17 which is a 41.1% upside from current levels.

ZIOPHARM Oncology Reports Q2 2020 Financial Results


(Click link above or copy, paste and hit enter in your browser for your report)

Another stock that is looking risky but with significant potential returns is ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) which has a beta of 2.21. The company has announced its Q2 2020 financial results and also provided a corporate update. During the quarter the company posted a net loss of $18.6 million or $0.09 per share topping analysts' estimates of a loss of $0.10 per share. This compares to a net loss of $14.6 million or $0.09 per share in Q2 2019. At the end of the quarter, the company had $153.5 million in cash and equivalents.

Currently, there is a $14 million prepayment remaining for the work the company will carry at MD Anderson under its R&D agreements. Research and development expenses were up $2.1 million YoY due to the increase in clinical studies.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.


comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.